1Van oosterom AT, Judson J, Verveij E, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study[J]. The Lancet, 2001,358:1421-1423.
2Mazur MT, Clark HB. Gastric stromal tumors:reappraisal of histogenesis[J]. Am J Surg Pathol, 1993,7(16):507-519.
3Miettinen M, J Y Blay, L H Sobin. Mesenchymal tumors of the stomach. WHO classification of tumours. Pathology and genetics of tumours of digestive system[M]. Lyon: IARC Press, 2000.62-65.
4Miettinen M, Sarlomo-Rikala M, Lassota J. Gastrointestinal stromal tumors:recent advances in understanding of their biology[J].Hum Pathol, 1999,30:1213-1220.
5Deininger MW,Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia[J]. Blood, 2000,96:3343-3356.
6Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor[J]. N Eng J Med, 2001, 344(14):1052-1056.
7Blanks CD, von Mehren M, Tuveson S, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patient with unresectable or metastatic expressing c-kit(CD117)[J].Proc ASCO, 2001, 20(pt 1):1a.abstracts1.
8Demetri GD, von Mehren M, Blande CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Eng J Med, 2002,347(7):472-480.
9Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib:a centre-based study of 17 patients[J]. B J C, 2003,89:460-464.
